Establishment Labs Hldgs Inc Stock Price, News & Analysis

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will release its financial results for the quarter ending March 31, 2023, post-market on May 8, 2023. A conference call to discuss the results is scheduled for 4:30 PM ET on the same day. Interested participants can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers. The event will also be available via live and archived webcast on the Establishment Labs investor relations webpage.

Establishment Labs specializes in medical technology focused on women's health, offering products like the Motiva® breast devices, which are backed by over 200 patents. The company operates two manufacturing facilities in Costa Rica, adhering to strict regulatory standards.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced a public offering of 1,100,000 common shares priced at $71.50, with gross proceeds estimated at $78.7 million. The offering, scheduled to close on April 27, 2023, includes a 30-day option for underwriters to purchase an additional 165,000 shares. Proceeds from the offering will be allocated for general corporate purposes, including sales and marketing, research and development, and working capital. Jefferies, J.P. Morgan, Citigroup, and TD Cowen are the joint book-running managers for this offering, which was filed under a prospectus supplement dated April 24, 2023.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has initiated a public offering of its common shares, with a possible additional 15% for underwriters. The offering's proceeds will fund general corporate needs, including sales, marketing, research, and working capital. Market conditions will dictate the offering's completion and terms. Jefferies, J.P. Morgan, Citigroup, and TD Cowen are the joint book-running managers, while BTIG acts as co-manager. The offering materials are detailed in a prospectus supplement filed under the company's existing shelf registration.

This action reflects Establishment Labs' commitment to advancing women’s health through its innovative Femtech solutions, including the Motiva® devices. These devices have redefined safety and satisfaction standards in 85 countries.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced preliminary unaudited financial results for Q1 2023, reporting revenue of approximately $46.5 million, a significant increase from $38.5 million in Q1 2022. The company's cash balance is projected at $42.8 million, while total debt, including principal and interest, is expected to be around $184.0 million. These preliminary results are subject to change pending audits. Establishment Labs focuses on women’s health and offers innovative solutions in breast aesthetics and reconstruction, with a strong portfolio including the Motiva® devices.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) presented a three-year follow-up report from the Motiva US IDE Study at The Aesthetic Meeting 2023 in Miami, Florida. The study involved 451 primary augmentation patients with a compliance rate of 92.4%. Key findings showed low complication rates: capsular contracture at 0.5%, rupture at 0.6%, and infection at 0.9%. The overall complication rate was reported at 8.4%. Dr. Caroline Glicksman, the study's Medical Director, noted the consistent clinical outcomes, highlighting the performance of Motiva implants and signaling hope for eventual FDA approval. The Motiva device remains under investigation and is not FDA-approved for commercial sale in the United States.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has launched its innovative Mia Femtech™ in Japan, aimed at enhancing breast aesthetics and addressing the specific needs of women in the region. This launch follows a decade of recognizing unmet demands in traditional breast augmentation. Mia Femtech offers a minimally invasive solution, requiring only 15 minutes and no general anesthesia, with minimal downtime. The procedure is offered at prestigious clinics in Tokyo and Osaka, marking significant growth potential as it creates a new category in breast aesthetics globally. Establishment Labs has delivered over three million Motiva® devices since 2010, establishing high safety and satisfaction standards in breast health.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in The Aesthetic Meeting 2023, occurring from April 19-23 in Miami, Florida. Dr. Caroline Glicksman will present an update on the Motiva US IDE Study during the event on April 20 at 3 PM ET. The Motiva Implants, currently not FDA-approved for commercial use in the U.S., are under clinical investigation. Establishment Labs focuses on women's health and wellness through advanced medical technology, providing breast aesthetics and reconstruction solutions. Motiva devices have set safety standards in over 85 countries since 2010.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has achieved a significant milestone by surpassing three million Motiva® devices sold globally, with less than 1% device-related complications reported over 12 years. This reflects the company's commitment to advancing women's health and wellness in breast aesthetics and reconstruction. CEO Juan José Chacón-Quirós highlighted their innovation-driven approach, while Dr. Heather Brennan emphasized the upcoming Sulàyöm Campus that will more than double manufacturing capacity. The company continues to prioritize safety and clinical performance, supported by extensive research and patent filings.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced partnerships with four clinics in Europe and one in Japan for its Mia Femtech™ product. This rollout marks a significant step for the company as it seeks to expand its innovative breast aesthetics offerings. Clinics in Sweden, Switzerland, and Spain are among the new partners, highlighting strong interest in the Mia brand. The CEO expressed optimism about further partnerships and market potential. However, it's important to note that Mia Femtech is not commercially available in the EU or the US at this time.